England's health-technology assessor and clinical guidance body
UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.
Three BBC investigations have revealed repeated failures in UK cancer care: a final review has found harm from misdiagnosis and inappropriate treatment by former Belfast neurologist Michael Watt; Coventry patients were prescribed temozolomide for years with little evidence of benefit; and England is missing cancer-treatment targets, with only 69.9% starting within 62 days. Officials and families are demanding answers.
The Guardian reports a government review has proposed triaging ADHD patients to a needs-based system, offering targeted support without necessarily requiring a formal diagnosis. The plan aims to relieve NHS waiting lists and focus help on those most in need, while raising concerns about potential rationing of care.
The Sentinel Stroke National Audit Programme shows only 6.4% of stroke patients in England, Wales and Northern Ireland receive the recommended three hours of rehabilitation per day in the first quarter of 2026. The Stroke Association warns this underlines a system under pressure as the burden of stroke grows, with costs reaching £25.7bn a year and social care bearing much of the burden. The Department of Health and Social Care says the NHS is striving to improve rapid support and long-term rehabilitation.